Zoetis Inc. (NYSE:ZTS) Shares Sold by Tributary Capital Management LLC

Tributary Capital Management LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,892 shares of the company’s stock after selling 110 shares during the period. Tributary Capital Management LLC’s holdings in Zoetis were worth $565,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Sarasin & Partners LLP increased its position in shares of Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after acquiring an additional 1,904,899 shares during the last quarter. Swedbank AB acquired a new stake in shares of Zoetis during the first quarter valued at about $210,815,000. International Assets Investment Management LLC increased its position in shares of Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after acquiring an additional 937,700 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Zoetis by 7,608.6% in the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock valued at $144,874,000 after purchasing an additional 824,843 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after purchasing an additional 414,605 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $180.01 on Monday. The business’s fifty day moving average price is $189.10 and its 200 day moving average price is $177.89. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The stock has a market capitalization of $81.55 billion, a PE ratio of 35.23, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period last year, the business posted $1.41 earnings per share. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 33.86%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.